BIB241115C67000
- 4.82
- 0.000.00%
Ultra Nasdaq Biotechnology Prosharesのニュース一覧
AstraZeneca's China Business Under Spotlight Amid Fraud Case
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Arcus Says Gilead-partnered Cancer Therapy Cut Death Risk by 36%
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
10 Health Care Stocks Whale Activity In Today's Session
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451
AstraZeneca Shares Are Trading Lower Following a Report Suggesting That the Company's Insurance Fraud Involved Senior Executives in China.
Vertex Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Issued FY24 Product Revenue Guidance Above Estimates. Also, Morgan Stanley Maintained an Equal-Weight Rating on the Stock and...
Arcellx Issues Updates on Anito-cel Clinical Trials
Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
Gilead Sciences's Earnings: A Preview
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Vertex Pharmaceuticals Analyst Ratings
美股收盘：特朗普、哈里斯概念股一同上涨 中概股稳中有升
Vertex Raises 2024 Product Revenue Outlook Following Q3 Beats
Vertex Pharmaceuticals Non-GAAP EPS of $4.38 Beats by $0.25, Revenue of $2.77B Beats by $80M
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Editas Downgraded to Market Perform by Raymond James
阿斯利康公布口服减肥药试验数据，四周助用药患者减重近6%